GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119

被引：42

作者：

Kang, Sang-Uk ^{[1
]}

机构：

[1] Kosin Univ, Dept Life Sci, Pusan, South Korea

来源：

DRUG DISCOVERY TODAY | 2013年 / 18卷 / 23-24期

关键词：

PROTEIN-COUPLED RECEPTOR; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; GLUCOKINASE ACTIVATORS; INSULIN-SECRETION; GLYCEMIC CONTROL; DISCOVERY; INHIBITORS; POTENT; ACID; THERAPY;

D O I：

10.1016/j.drudis.2013.09.011

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Ever since its advent as a promising therapeutic target for type 2 diabetes mellitus (T2DM), G-protein-coupled receptor 119 (GPR119) has received much interest from the pharmaceutical industry. This interest peaked in June 2010, when Sanofi-Aventis agreed to pay Metabolex (Cymabay Therapeutics) US$375 million for MBX-2982, which was a representative orally active GPR119 agonist. However, Sanofi-Aventis opted to terminate the deal in May 2011 and another leading GPR119 agonist, G5K1292263, had a loss of efficacy during its clinical trial. In this review, I discuss the pros and cons of GPR119 through a strengths, weaknesses, opportunities, and threats (SWOT) analysis and propose development strategies for the eventual success of a GPR119 agonist development program.

引用

页码：1309 / 1315

页数：7

共 56 条

[1] Metformin: an old but still the best treatment for type 2 diabetes [J].